Ghisallo bought 6,26,000 shares of Biocon for ₹25.04 Cr at ₹400.00 apiece in a block deal.
A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.
Ghisallo Capital Management is a New York-based hedge fund investing in listed Indian equities.
